11月3日，康希诺生物盘中下跌5.06%，报24.4港元，成交额3538.33万港元。
消息面上，公司近日披露持续督导保荐代表人变更，中信证券委派王天祺接替徐峰林，与焦延延共同履职；该事项本身偏程序性，未改变公司持续督导安排。
此前公司三季报显示，前三季度营收8.82亿元，同比增长27.40%；归母净利润1629.13万元，同比增长12.82%。但第三季度单季净利润1701.21万元，同比下降39.08%，叠加当日生物科技板块整体偏弱，股价承压。
康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.